Danaher posts Q3 2026: Revenue $6.6B, Net earnings $1.2B, Adjusted EPS $2.11

Danaher reported Q3 2026 revenue of $6.6B, up 8.5% YoY, with net earnings of $1.2B. Adjusted EPS rose 11.5% to $2.11. Core sales growth, excluding respiratory testing, was 5.5%. The company raised full-year adjusted EPS guidance to $8.57–$8.62, citing strong operational execution.

Original reporting
Published Oct 21, 2026, 10:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Danaher posts Q3 2026: Revenue $6.6B, Net earnings $1.2B, Adjusted EPS $2.11 — source image
Decision brief

The 30-second read

$DHRBullishMed
01

Why it matters

The earnings beat and guidance raise are likely to boost investor confidence and support the stock price.

02

Market read

Strong earnings and raised guidance make Danaher a focal point for industrial and healthcare investors.

03

What to watch

Potential headwinds from respiratory testing demand slowdown could temper growth.

Relevance 8/10Novelty 8/10Timing: post‑release today

Background

Danaher’s Q3 earnings beat expectations and the company raised its full‑year EPS outlook.

Company-level read

Ticker impact

$DHRBullishHigh confidence
Context

Danaher reported Q3 2026 results with revenue $6.6B, EPS $1.71 and raised full-year adjusted EPS guidance to $8.57‑$8.62.

Expected impact

likely upward pressure as investors price in higher earnings expectations

Evidence & confidence

The company increased its full‑year adjusted EPS guidance, indicating better profitability and cash generation, which typically supports a price rally.

Market effects

Positive for life‑sciences and diagnostics equipment sector as Danaher’s growth signals demand strength.

U.S. market may see modest uplift in industrial and healthcare stocks.

Limited to investors tracking large‑cap industrial conglomerates.

Counterpoint

If the market has already priced in the guidance lift, the stock could face a short‑term pullback.

Key entities

  • Danaher Corp

    Industrial conglomerate reporting Q3 2026 results.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.